BCM
ELVN icon

BML Capital Management’s Enliven Therapeutics ELVN Stock Holding History

BML Capital Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,100
Closed -$881K – 30
2024
Q1 		$881K Buy
50,100
+100
+0.2% +$1.53K 0.58% 25
2023
Q4 		$692K Hold
50,000
– – 0.52% 27
2023
Q3 		$683K Sell
50,000
-24,232
-33% -$408K 0.63% 16
2023
Q2 		$1.52M Sell
74,232
-137,947
-65% -$2.79M 1.36% 16
2023
Q1 		$4.65M Sell
212,179
-542,265
-72% -$11M 4.02% 10
2022
Q4 		$12.3M Buy
+754,444
New +$12.1M 11.79% 2

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BML Capital Management's ELVN Position: Q2 2024 in Review

BML Capital Management sold out of Enliven Therapeutics (ELVN) in Q2 2024, closing a stake of 50,100 shares — an estimated $881K sold.

BML Capital Management first reported a position in ELVN in Q4 2022 and held it in 6 quarters. The position peaked at $12.3M in Q4 2022. 93 funds tracked by Wall St. Rank hold ELVN as of Q2 2024.

  • BML Capital Management reported no remaining Enliven Therapeutics position as of Q2 2024 after selling out during the quarter.
  • BML Capital Management sold 50,100 Enliven Therapeutics shares in Q2 2024, an estimated $881K.
  • BML Capital Management first reported a position in Enliven Therapeutics in Q4 2022 and held it in 6 quarters.
  • BML Capital Management's Enliven Therapeutics position peaked at $12.3M in Q4 2022.
  • 93 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2024.

Based on BML Capital Management's 13F filing for Q2 2024, filed 7 Aug 2024.